# Brain Mets - Capecitabine Plus Sunitinib and WBRT

> **NCT00570908** · PHASE2 · TERMINATED · sponsor: **Baylor Breast Care Center** · enrollment: 12 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** sunitinib
- **DRUG:** capecitabine
- **RADIATION:** WBRT

## Key facts

- **NCT ID:** NCT00570908
- **Lead sponsor:** Baylor Breast Care Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-02
- **Primary completion:** 2013-09
- **Final completion:** 2013-09
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Due to poor accrual this study is being closed to accrual
- **Last updated:** 2014-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00570908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00570908, "Brain Mets - Capecitabine Plus Sunitinib and WBRT". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00570908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*